Kathryn Dzintars, Pharm.D., BCPS



The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 in adults at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk for progression includes age > 60, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
  • Authorized for treatment within the first 5d of symptomatic COVID-19 illness.
  • In February 2023, the FDA updated the EUA by removing the need for a positive COVID-19 viral test to prescribe the medication

Molnupiravir is NOT authorized for:

  • Patients < 18 years of age
  • Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
  • Use longer than 5 consecutive days
  • Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 6, 2023